Introduction
============

Renal colic is usually manifested clinically as a very painful and troublesome condition which appears unilaterally on the flank to the groin suddenly or periodically ([@B1], [@B2]). The condition afflicts 5-12% of the population in industrial societies at least once in their life and its recurrence rate is approximately 50% ([@B1]). The pain is usually attributed to contraction of ureter soft muscles in response to the presence of stone ([@B3]-[@B5]). Therefore, the most important consideration in the emergency management of renal colics is pain control/relief ([@B5], [@B6]). Various therapeutic strategies are employed to alleviate the pain due to renal calculi and some studies have recommended the use of NSAID, especially ketorolac, as the first analgesic for renal calculi ([@B5], [@B7]-[@B10]). However, disadvantages such as lack of availability, high cost, the risk of gastrointestinal hemorrhage, and acute renal insufficiency have led to a greater use of opioids such as meperidine and morphine or their concomitant use in clinical settings compared to NSAIDs ([@B1], [@B11], [@B12]). On the other hand, there is an ample evidence in relation to pain relief with the use of serotonin re-uptake inhibitors such as citalopram in patients with acute and chronic renal insufficiency, in cases of visceral pain, heat sensitivity, thermal pain, peritoneal dialysis, peritonitis and neuropathic injuries ([@B13], [@B14]). Although the synergistic effects of opioids such as morphine and the group of analgesics such as NSAIDs have been established on relieving acute pain due to renal stones, no studies today have evaluated the effects of concomitant administration of opioids and other analgesic agents, such as serotonin re-uptake inhibitions. Therefore, the present study was undertaken to evaluate the presence or absence of synergistic or additive analgesic effect of morphine and citalopram on relieving acute renal stone pain.

Methods
=======

***Study design and setting***

The present double-blind randomized clinical trial was carried out during a six-month period from October 2012 to March 2013 in the emergency department of Al-Zahra Hospital, Isfahan, Iran. The protocol of the study was prepared based on Helsinki declaration and approved by ethics committee of Isfahan University of Medical Sciences. The study was registered in Iranian registry of clinical trial (IRCT2014020812072N1). All patients signed consent form before including to the study. ***Participants***

The subjects were patients with acute renal colic, referring to the emergency department of Al-Zahra Hospital. The inclusion criteria consisted of an age range of 18-55, a clinical diagnosis of acute colicky pain, pain severity of 7-10 based on visual analogue scale (VAS), and patients' consent form to participate in the study. The exclusion criteria consisted of pregnancy or suspected of being pregnant, contraindication in relation to taking morphine and citalopram based on drug catalog, a history of dependence on opioids or SSRIs, receiving an analgesic during a six-hours period before presentation, peritonitis or peritoneal symptoms and signs, any disease preventing communication, and patient's decision to leave the study.

***Intervention***

All the patients underwent a urine analysis and an ultrasound examination. The final diagnosis was reached in each patient based on initial clinical diagnosis using the examinations above. The patients were randomly assigned to two groups. The subjects in group one received an intravenous injection consisting of 5 mg of morphine sulfate plus placebo (normal saline with the same volume as that in group two) and subjects in group two received an intravenous injection consisting of 5 mg of morphine sulfate plus 20 mg of citalopram. During the study period, none of the patients, physicians and nurses, and the medical care team members were aware of the study procedures. Preparation and injection of medications were carried out by two nurses; the nurses prepared the medications were blind to drugs of each patient. All the syringes had the same shape. Randomization and registration of data were carried out by the chief researcher who was the only person aware of the study procedures. In order to confirm the diagnosis, all the patients were subjected to an ultrasound examination of kidneys and the urinary tract. The ultrasonography was not performed for patients with a documented history of renal calculi or patients recovering from renal calculi and referring with a similar episode. Visualization of a renal stone by a radiologist during ultrasound examination or a report of hydronephrosis on the painful side confirmed the diagnosis. Passage of stone through the urethra and direct visualization of stone confirmed the diagnosis, too. The medications were administered intravenously in the same manner for all the patients and each of them received a proper medications dose based on a timetable. Any drug side effect was managed by standard protocols of the emergency department.

***Statistical analyses***

The sample size in the present study was calculated at 45 subjects in each group, by considering a 95% confidence interval, an 80% power of the test, the variance of pain severity 1.7, and the minimum significant difference 0.8. Data were analyzed using STATA ver. 11.0. Independent t-test and chi-squared test were used to evaluate the quantitative and qualitative variables, respectively. Two-way ANOVA and Bonferroni post hoc test were applied to assess inter- and intra-group differences in pain severity based on VAS at study intervals. Kaplan-Meier estimates were used to evaluate treatment success and log rank test to compare the treatment regiments. To this end, treatment success was defined as a decrease in pain severity at least three points on VAS. Statistical significance was defined at P\<0.05.

Results
=======

Ninety patients with acute colicky pain were equally assigned to two groups for treatment with morphine + placebo and morphine/citalopram. The mean ages of the subjects in two groups were 35.36±9.5 and 35.56±10.4 years, respectively (p=0.92). In the morphine/placebo and morphine/citalopram groups, 33 (73.3%) and 32 (71.1%) subjects were male, respectively (p=0.92). The mean VAS at the time of admission in the morphine/placebo and morphine/citalopram groups were 7.53±1.66 and 7.07±1.85, respectively (p=0.22). Twenty minutes after the first injection, the mean VAS decreased to 6.4±2.3 and 4.0±3.1 in the morphine/placebo and morphine/citalopram groups, respectively. The decrease in pain severity in the morphine/citalopram group was significantly compared to the morphine/placebo group and the time before administration of the medications (baseline) (p\<0.001). In contrast, administration of morphine and placebo did not have a significant effect on pain severity at this interval (p=0.32). The mean pain severity 20 minutes after the second injection meaningfully decreased (40 minutes after the first injection) in the morphine/citalopram group \[mean (SD)= 1.6 (1.6); p\< 0.001\] and in the morphine/placebo group \[mean (SD)= 2.31 (1.72); p\<0.001\]. Pain severity was not considerably different between the two study groups (p\>0.99). The third injection did not have any extra effect on pain intensity in both groups (p\>0.99) ([Figure 1](#F1){ref-type="fig"}). Two-way ANOVA showed that the therapeutic interventions resulted in a significant decrease in pain severity (df: 1.7; F=66.9; p\<0.001). Kaplan-Meier curve showed that the first injection was successful in relieving pain in 15 (33.3%) and 26 (57.8%) subjects in the morphine/ placebo and morphine/citalopram groups, respectively. The second injection of these medications resulted in therapeutic success in 35 (87.8%) and 42 (95.6%) subjects in the above groups, respectively. Log rank test showed a remarkable difference in the treatment success between the two groups (p=0.001) ([Figure 2](#F2){ref-type="fig"}).

Discussion
==========

Based on the findings of present study, combination of morphine sulfate and citalopram has significantly higher success rate in pain control of renal colic during the first 20-minute period in comparison to morphine alone. However, administration of morphine and placebo did not have a noteworthy effect on pain severity at this interval. There were no meaningful differences in the second and third dose administrations between two groups regarding changes in pain severity ([figure 1](#F1){ref-type="fig"}). But, the results of the log rank test revealed a significantly higher success rate in morphine/citalopram group at the same time. It means that, although the two groups were able to equal changes in pain severity during a 60-minute period, but the failure rate was considerably higher in patients received morphine alone. Previous studies have shown that use of morphine results in an increase of serotonin levels in the brain; also, use of citalopram increases serotonin concentration by inhibiting its re-uptake ([@B15]). On the other hand, the tranquilizing effect of citalopram helps relieving pain in these patients. Sacerdote et al. concluded that the analgesic effect of some antidepressant seems to be related to an activation of the endogenous opioid system mediated by serotonin ([@B16]). Therefore, it seems that the combination of a serotonin re-uptake inhibitor and morphine sulfate have synergistic effects regarding pain control. Since citalopram has a minimum side effects compared to other inhibitors of serotonin re-uptake inhibitors, it could be considered as a suitable choice for this object. Campo and their colleague revealed the potential effects of citalopram for functional pediatric recurrent abdominal pain control ([@B17]). A randomized double-blind study showed a moderate analgesic effect of citalopram in patients with Pain disorder and declared that it appears to be not correlated to changes in depressive scores ([@B18]). Also, citalopram had a positive effect on chronic pelvic pain control and relieving peripheral neuropathic pain in diabetic patients ([@B19], [@B20]). The present study showed that citalopram in combination with morphine causes to increase the efficacy of morphine in relieving the pain of renal colic. Further studies are needed to evaluate of action mechanisms and potential complications.
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![The Kaplan-Meier curve to show the success rate in patients' underling treatment with two drug regimens of morphine + placebo and morphine + citalopram. Log rank test showed a significant difference in treatment success between the two groups (P=0.001).](emerg-2-26-g002){#F2}

***Limitation***

Although the VAS is a standard scoring system for evaluation of pain severity, the use of functional ([@B21]) and behavioral ([@B22]) indices, as an adjunct to VAS, could be more accurate. However, the study power of 99% made the findings of the study valid.

Conclusion:
===========

It seems that the combination of citalopram and morphine sulfate causes to an increased efficacy and higher success rate in pain control of patients presented to the emergency department with a complaint of renal colic.
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